Not long after a first-of-its-kind blood test received approval to evaluate patients with mild traumatic brain injury, headlines dubbed it a “concussion test.” But experts in biomarkers are clarifying certain misconceptions about what the test can and can’t reveal.
“It’s used to rule out the need for a [computed tomography] scan within 12 hours” after a suspected mild traumatic brain injury (TBI), said Steven Richieri, MBA, president and chief operating officer of San Diego-based Banyan Biomarkers Inc, which developed the test.
Voelker R. Taking a Closer Look at the Biomarker Test for Mild Traumatic Brain Injury. JAMA. 2018;319(20):2066–2067. doi:10.1001/jama.2018.4644
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: